Highly modulated genes (0.7 < fold change > 1.3) observed in patients with RA after comparison between responders (n = 8) and nonresponders (n = 17) to methotrexate (MTX) monotherapy.
| Symbol | Gene | Process | Fold Change (MTX-NR vs MTX-R) |
|---|---|---|---|
| Apoptosis | |||
| HTRA2 | HtrA serine peptidase 2 | Proapoptotic | 0.69 |
| CAVI | Caveolin 1 | Proapaptotic (cell death TNF-induced) | 0.65 |
| CASP8AP2 | Caspase 8 associated protein 2 | Proapoptotic | 0.54 |
| PRKDC | Protein kinase, DNA-activated, catalytic polypeptide | Proapoptotic | 0.49 |
| BCL2A1 | BCL2-related protein A1 | Antiapoptotic | 1.62 |
| MXD1 | MAX dimerization protein 1 | Antiapoptotic | 1.43 |
| TNIP1 | TNFAIP3 interacting protein 1 | Antiapoptotic TNF-dependent | 1.35 |
| BTG2 | BTG family, member 2 | Antiapoptotic | 1.32 |
| Immune response | |||
| CCL4 | Chemokine (C-C motif) ligand 4 | Inflammatory response | 1.89 |
MTX-NR: nonresponders to methotrexate; MTX-R: responders to MTX; TNF: tumor necrosis factor.